Supernus Pharma (SUPN) Tops Q2 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Supernus Pharma (SUPN) Tops Q2 EPS by 5c

Supernus Announces Second Quarter 2016 Financial Results

August 2, 2016 4:30 PM EDT

Second quarter 2016 product prescriptions totaled 123,758, a 38.9% increase over the second quarter of 2015.Net product sales for second quarter 2016 were $50.3 million, a 46.9% increase over the second quarter of 2015.Operating income for second quarter 2016 was $10.4 million compared to $3.1 million in the second quarter of 2015.   Diluted earnings per share in the second quarter were $0.18 compared to $0.03 in the same period last year.   Enrollment completed in SPN-812 Phase IIb trial. Enrollment for SPN-810 Phase III trials expected to continue into 2017.

ROCKVILLE, Md., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:... More